#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dermatitis atopic Breast cancer metastatic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Haemophilia B with anti factor IX Breast cancer metastatic Graft versus host disease Parkinson's disease Myeloid leukaemia Congenital hypotransferrinaemia Bone marrow disorder Factor VIII deficiency Heritable pulmonary arterial hypertension Lennox-Gastaut syndrome Subdural haematoma Nasopharyngeal cancer Castleman's disease Chronic graft versus host disease Non-renal cell carcinoma of kidney More trials…

    Learn about Rare Diseases

    Undifferentiated sarcoma – Life with Disease Turner’s syndrome – Diagnostics Systemic mastocytosis – Diagnostics Focal segmental glomerulosclerosis Fragile X syndrome – Trials in Disease Brain stem glioma – Life with Disease Leiomyosarcoma metastatic – Treatment Angiosarcoma – Life with Disease Alport’s syndrome – Basic Information Angiosarcoma More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Mps-213 Dazostinag Itraconazole Progesterone, Micronised Quinidine Sulfate Lutikizumab TRIGLYCERIDES MEDIUM CHAIN Maridebart Cafraglutide Psma-11 Azelastine Gallium (68Ga) Chloride Lisaftoclax Hst-1011 Meloxicam Ulipristal Acetate Thymalfasin Orismilast Calcium Pantothenate Bp VISUGROMAB Thiotepa More therapies…

    Learn about Your Condition

    Ectopic pregnancy Shock Turner's syndrome Glomerulonephritis chronic Desmoid tumour Rosai-Dorfman syndrome Dermatitis atopic Bronchostenosis Langerhans cell sarcoma Herpes virus infection Haemofiltration Haemodynamic instability Chorioretinitis Infertility male IgA nephropathy More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Azienda Ospedaliero Universitaria Consorziale Policlinico…

Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari

Piazzale Giulio Cesare 11, Bari, 70124, Italy

Want to learn more about this study or check if you can participate? Contact us.

  • Comparing piperacillin-tazobactam and meropenem for treating bloodstream infections caused by cephalosporin-resistant bacteria in adult patients

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Bacteraemia
    Investigated Drugs:
    • Meropenem Anhydrous
    • Piperacillin
    • Tazobactam
    Italy

  • Study of sonrotoclax plus obinutuzumab or rituximab compared to venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • N-[4-({[(1R,4R)-4-Hydroxy-4-Methylcyclohexyl]Methyl}Amino)-3- Nitrobenzene-1-Sulfonyl]-4-(2-{(2S)-2-[2-(Propan-2-Yl)Phenyl]Pyrrolidin1-Yl}-7-Azaspiro[3.5]Nonan-7-Yl)-2-[(1H-Pyrrolo[2,3-B]Pyridin-5- Yl)Oxy]Benzamide
    • Obinutuzumab
    • Rituximab
    Austria Belgium Czechia Denmark France Germany +6

  • Study of DNTH103 Treatment for Adults with Chronic Inflammatory Demyelinating Polyneuropathy: Comparing Effectiveness with Placebo

    Recruiting

    3 1
    Investigated Drugs:
    • Dnth103
    Belgium Bulgaria Croatia Denmark France Germany +6

  • Study on the Effectiveness and Safety of Colesevelam Hydrochloride for Patients with Idiopathic Bile Acid Diarrhea (BAD)

    Recruiting

    2 1
    Investigated Drugs:
    • COLESEVELAM HYDROCHLORIDE
    Belgium Denmark Italy Romania Spain

  • Study of RO7790121 (afimkibart) for Treatment and Long-term Management in Adults with Moderate to Severe Crohn’s Disease

    Recruiting

    3 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • Ro7790121
    Austria Belgium Bulgaria Croatia Czechia Denmark +10

  • Study on Baxdrostat and Dapagliflozin for Preventing Heart Failure in Patients at High Risk

    Recruiting

    3 1 1
    Investigated Drugs:
    • Baxdrostat
    • Dapagliflozin
    Bulgaria Czechia Denmark France Germany Greece +8

  • Study of gemtuzumab ozogamicin with chemotherapy for adults aged 18-60 with newly diagnosed favorable-intermediate-risk acute myeloid leukemia

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Acute myeloid leukaemia
    Investigated Drugs:
    • Gemtuzumab Ozogamicin
    • Fludarabine
    • Treosulfan
    Italy

  • Study on the Effects of Tumor Removal in Patients with Metastatic Kidney Cancer Treated with Nivolumab and Ipilimumab Combination

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Metastatic renal cell carcinoma
    Investigated Drugs:
    • Axitinib
    • Cabozantinib
    • Ipilimumab
    Italy

  • Study of atropine eye drops (0.

    Recruiting

    3 1
    Investigated Diseases:
    • Myopia
    Investigated Drugs:
    • Atropine Sulfate Monohydrate
    Italy Poland Spain

  • Study of Vemurafenib and Rituximab for Untreated Hairy Cell Leukemia Patients

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Hairy cell leukaemia
    Investigated Drugs:
    • Cladribine
    • Rituximab
    • Vemurafenib
    Italy
1 2 3 … 7
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!